insulin – pharmacology, types of regimens, and adjustments

25/06/2015 InsulinPharmacology,TypesofRegimens,andAdjustmentsEndotextNCBIBookshelf

http://www.ncbi.nlm.nih.gov/books/NBK278938/?report=printable 1/24

NCBIBookshelf.AserviceoftheNationalLibraryofMedicine,NationalInstitutesofHealth.

DeGrootLJ,BeckPeccozP,ChrousosG,etal.,editors.Endotext[Internet].SouthDartmouth(MA):MDText.com,Inc.2000.

InsulinPharmacology,TypesofRegimens,andAdjustmentsLisaKroon,PharmD,CDEProfessorandExecutiveViceChair,DepartmentofClinicalPharmacy,SchoolofPharmacy,UniversityofCaliforniaSanFrancisco,SanFrancisco,[email protected]

IraD.Goldfine,M.D.ProfessorofMedicine,DepartmentofMedicine,DiabetesandEndocrineResearch,UniversityofCaliforniaSanFrancisco/Mt.ZionMedicalCenter,SanFrancisco,[email protected]

SinanTanyolac,M.D.VisitingScientist,DepartmentofMedicine,UniversityofCaliforniaSanFrancisco,SanFrancisco,[email protected]

LastUpdate:October1,2010.

INTRODUCTION

Withtheintroductionofseveralnewinsulinssince1996,insulintherapyoptionsfortype1andtype2diabeticshaveexpanded.Insulintherapiesarenowabletomorecloselymimicphysiologicinsulinsecretionandthusachievebetterglycemiccontrolinpatientswithdiabetes.Thischapterreviewsthepharmacologyofinsulins(usingacomparativeapproach),typesofinsulinregimensandtherapeuticadjustmentofthem,andprovidesanoverviewofinsulinpumptherapy.

PHARMACOLOGY

In1922,Canadianresearcherswerethefirsttodemonstrateaphysiologicresponsetoinjectedanimalinsulininapatientwithtype1diabetes.In1955,insulinwasthefirstproteintobefullysequenced.Theinsulinmoleculeconsistsof51aminoacidsarrangedintwochains,anAchain(21aminoacids)andBchain(30aminoacids)thatarelinkedbytwodisulfidebonds (Figure1).ProinsulinistheinsulinprecursorthatistransportedtotheGolgiapparatusofthebetacellwhereitisprocessedandpackagedintogranules.Proinsulin,asinglechain86aminoacidpeptide,iscleavedintoinsulinandCpeptide(aconnectingpeptide)botharesecretedinequimolarportionsfromthebetacelluponstimulationfromglucoseandotherinsulinsecretagogues.WhileCpeptidehasnoknownphysiologicfunction,itcanbemeasuredandifpresent,indicatesapersonhasfunctioningbetacells.

Figure1 InsulinStructure

Insulinexertsitseffectonglucosemetabolismbybindingtoinsulinreceptorsthroughoutthebody.Uponbinding,insulinpromotesthecellularuptakeofglucoseintofatandskeletalmuscleandinhibitshepaticglucoseoutput,thusloweringthebloodglucose.(seeInsulinsignalingandaction:glucose,lipids,protein)

Commerciallyavailableinsulinsareusedforallpatientswithtype1diabetesinwhominsulinisrequiredforsurvival,andforpatientswithtype2diabeteswhendiet/exercise,oralagentsandotherinjectablehypoglycemicagents(i.e.,incretinemimeticagents/GLP1analogs)nolongerprovideadequateglucosecontrol.

SourcesofInsulin

WiththeavailabilityofhumaninsulinbyrecombinantDNAtechnologyinthe1980s,useofanimalinsulindeclined

[1]



dramatically.Beefinsulin,beefporkandporkinsulinarenolongercommerciallyavailable.TheFDAmayallowforpersonalimportationofbeefinsulinfromaforeigncountryifapatientcannotbetreatedwithhumaninsulin .Beefinsulindiffersfromhumaninsulinby3aminoacidsandporkinsulindiffersbyoneaminoacid .

Currently,intheUSA,mostinsulinsusedareeitherhumaninsulinand/oranalogsofhumaninsulin.TherecombinantDNAtechniqueforhumaninsulininvolvesinsertionofthehumanproinsulingeneintoeitherSaccharomycescerevisiae(bakersyeast)oranonpathogeniclaboratorystrainofEscherichiacoli(Ecoli)whichserveastheproductionorganism.Humaninsulinisthenisolatedandpurified .

InsulinAnalogs

RecombinantDNAtechnologyhasallowedforthedevelopmentandproductionofanalogstohumaninsulin.Withanalogs,theinsulinmoleculestructureismodifiedslightlytoalterthepharmacokineticspropertiesoftheinsulin,primarilyaffectingtheabsorptionofthedrugfromthesubcutaneoustissue.TheB26B30regionoftheinsulinmoleculeisnotcriticalforinsulinreceptorrecognitionanditisinthisregionthataminoacidsaregenerallysubstituted .Thus,theinsulinanalogsarestillrecognizedbyandbindtotheinsulinreceptor.ThestructuresofthreeinsulinanalogsareshowninFigure2(insulinaspart,lisproandglulisine)andFigure3(insulinglargineanddetemir).

Figure2 InsulinAspart,GlulisineandLisproStructures

[2]

[3]

[4] [5] [6] [7] [8] [9] [10] [11]

[12]



Figure3 InsulinGlargineandDetemirStructures

Becauseinsulinanalogsaremodifiedhumaninsulin,thesafetyandefficacyprofilesoftheseinsulinshavebeencomparedtohumaninsulin .InsulinandIGF1receptorbindingaffinities(IGFinsulinlikegrowthfactor),metabolicandmitogenicpotenciesofinsulinlispro,insulinaspart,insulinglargineandinsulindetemirrelativetohumaninsulinhasbeenassessed.Insulinlisproandaspartaresimilartohumaninsulinonalloftheaboveparameters,exceptinsulinlisprowasfoundtobe1.5foldmorepotentinbindingtotheIGF1receptorcomparedtohumaninsulin.Insulinglarginewasfoundtohavea6to8foldincreaseinmitogenicpotencyandIGF1receptoraffinitycomparedtohumaninsulin.Insulindetemirwasfoundtotobemorethan5foldlesspotentthanhumaninsulininbiningtoIGF1.Whiletheclinicalsignificanceofthesedifferencesisnotknown,theylikelydonotrepresentanysignificantconcern .

Immunogenicity

Becauseporkandbeefinsulindifferfromhumaninsulinby1and3aminoacidsrespectively,theyaremoreimmunogenicthanexogenoushumaninsulin.Olderformulationsofinsulinwerelesspure,containingisletcellpeptides,proinsulin,Cpeptide,pancreaticpolypeptides,glucagons,andsomastostatin,whichcontributedtoimmunogenicityofinsulin .Componentsofinsulinpreparations(e.g.,zinc,protamine)andsubcutaneousinsulinaggregatesarealsothoughttocontributetoantibodyformation .Commerciallyavailablehumaninsulinsarenowvirtuallyfreeofcontaminantsandcontain



Patientswhoexperienceatrueallergicreactiontoinsulinoftenhavereceivedinsulininthepast,andexperiencetheallergicreactionafterinsulinisrestarted.AnotherallergicreactionseenwithanimalinsulinswasadelayedlocalreactionthatwasIgGmediated .InsulintherapycanalsoresultintheproductionofinsulinantibodiesoftheIgGclass,whichneutralizeinsulin.AnimmunologicalinsulinresistancecanoccurinpatientswithveryhightitersofIgGantibodies.

Lipodystrophyseenwithinsulinreferstotwoconditions:lipoatrophyandlipohypertrophy.Lipoatrophyisanimmunemediatedconditioninwhichthereislossoffatattheinsulininjectionsites .Lipoatrophyoccursmuchlessfrequentlywithpurifiedhumaninsulins.Treatmentforpatientswhowereonananimalinsulinwasinjectionwithhumaninsulinattheatrophiedsite.Lipohypertrophyisanonimmunologicalsideeffectofinsulinresultingfromrepeatedadministrationofinsulinatthesameinjectionsite.

Concentration

IntheUnitedStates,allinsulinsareavailableintheconcentrationof100units/ml(denotedasU100).Insulinsyringesaredesignedtoaccommodatethisconcentrationofinsulin.Regularhumaninsulin(HumulinR,Lilly)isavailableinamoreconcentratedinsulin,U500(500units/ml),howeverthispreparationisusedprimarilyinaspecializedinstitutionalsettingorforrarecasesofextremeinsulinresistance,whereverylargedosesofinsulin(generally>200unitsperday)arerequired.SpecificsyringesforU500insulinarenotavailableandextremecautionmustbetakenaseachmarkedunitonaU100syringewillactuallydeliver5unitsofinsulin.

OutsidetheUnitedStates,alessconcentratedinsulinpreparation,U40,(40units/ml)isstillavailableandsometimesused.SpecificU40syringesareusedwiththisinsulin.Itisimportantthatpatientstravelingfromonecountrytothenext,beawareoftheconcentrationofinsulintheyuse,andthattheappropriatesyringeisused.

PhysicalandChemicalProperties

Regularhumaninsuliniscrystallinezincinsulindissolvedinaclearsolution.Itmaybeadministeredbyanyparenteralroute:subcutaneous,intramuscular,orintravenous.Insulinaspart,glulisineandlisproarealsosolublecrystallinezincinsulin,butareintendedforsubcutaneous(subQ)injection.NPH,orneutralprotamineHagedorn,isasuspensionofregularinsulincomplexedwithprotaminethatdelaysitsabsorption.Insulinsuspensionsshouldnotbeadministeredintravenously.Allinsulins,exceptinsulinglargine,areformulatedtoaneutralpH.

LongactingInsulinglargineisasoluble,clearinsulin,andhasapHof4.0.ItsacidicpHiscriticalforitssubQabsorptioncharacteristicsandwillbediscussedfurtherunderpharmacokinetics.Insulinglargineshouldnotbemixedwithotherinsulins,andshouldonlybeadministeredsubcutaneously .

InsulindetemirisalongactinginsulinanalogthathasafattyacidcoupledtoitsothatitbindstoalbumininthesubQtissueresultingindelayedabsorption,proloningitsdurationofaction.Likeinsulinglargine,insulindetemirshouldnotbemixedwithotherinsulins,andshouldbeinjectedsubcutaneously.

Pharmacokinetics

Absorption

InsulinadministeredviaSCinjectionisabsorbeddirectlyintothebloodstream,withthelymphaticsystemplayingaminorroleintransport .TheabsorptionofhumaninsulinaftersubQabsorptionistheratelimitingstepofinsulinactivity.ThisabsorptionisinconsistentwiththecoefficientsofvariationofT50%(timefor50%oftheinsulindosetobeabsorbed)varying~25%withinanindividualandupto50%betweenpatients .Mostofthisvariabilityofinsulinabsorptioniscorrelatedtobloodflowdifferencesatthevarioussitesofinjection(abdomen,deltoid,gluteus,andthigh) .Forregularinsulin,theimpactofthisisa~2timesfasterrateofabsorptionfromtheabdomenthanothersubcutaneoussites .Theclinicalsignificanceofthisisthatpatientsshouldavoidrandomuseofdifferentbody

[20]

[21]

[22]

[23]

[24] [25]

[26]

[27]



regionsfortheirinjections.Forexample,ifapatientpreferstousetheirthighforanoontimeinjection,thissiteshouldbeusedconsistentlyforthisinjection.Forsimplicity,however,theabdomenisoftenrecommendedasthepreferredsiteofinjectionbecauseitistheleastsusceptibletofactorsaffectinginsulinabsorption(seeTable1).Insulinaspart,glulisineandlisproappeartohavelessdaytodayvariationinabsorptionratesandalsolessabsorptionvariationfromthedifferentbodyregions .Insulinglarginespharmacokineticprofileissimilarafterabdominal,deltoidorthighSCadministration .

AgeneralprincipleforfactorsthatcanalterinsulinabsorptionisthatwhenlocalbloodflowinthesubQtissueischanged,theabsorptionrateofinsulinwillalsobeaffected.AfactorthatincreasessubQbloodflowwillincreasetheabsorptionrateandviceversa.SeeTable1forfactorsthataffectinsulinabsorption.

Table1 FactorsAffectingInsulinAbsorption( )

Factor Comment

Exerciseofinjectedarea Strenuousexerciseofalimbwithin1hourofinjection.Clinicallysignificantforregularhumaninsulin.

Localmassage WhileitisOKtopressontheinjectionsitetopreventseepage,thesiteshouldnotberubbedvigorouslyormassaged.

Temperature Heatcanincreaseabsorptionrate.Avoidthesauna,shower,hotbathsoonafterinjection.Coldhastheoppositeeffect.

Siteofinjection Insulinisabsorbedfasterfromtheabdomen.Lessclinicallyrelevantwithrapidactinginsulins,insulinglargineandinsulindetemir.

Lipohypertrophy Injectionintohypertrophiedareasdelaysinsulinabsorption.

Jetinjectors Increaseabsorptionrate.

Insulinmixtures Absorptionratesareunpredictablewhensuspensioninsulinsarenotmixedadequately(i.e.,theyneedtoberesuspended).

Insulindose Largerdoseshavedelayinactionandincreasedduration.

Physicalstatus(solublevs.suspension)

Suspensioninsulinsmustbesufficientlyresuspendedpriortoinjectiontoreducevariability.

Distribution

CirculatinginsulinisdistributedinequilibriumbetweenfreeinsulinandinsulinboundtoIgGantibodies .Thepresenceofinsulinantibodiescandelaytheonsetofinsulinactivity,reducethepeakconcentrationoffreeinsulin,andprolongthebiologichalflifeofinsulin .

Elimination

Thekidneysandliveraccountforthemajorityofinsulindegradation.Normally,theliverdegrades~60%ofinsulinreleasedbythepancreas(insulindeliveredthroughportalveinbloodflow)andthekidneys~3545% .Wheninsulinisinjectedexogenously,thedegradationprofileisalteredsinceinsulinisnolongerdelivereddirectlytotheportalvein.ThekidneyhasagreaterroleininsulindegradationwithsubQinsulin(~60%),withtheliverdegrading~3040%

.

Becausethekidneysareinvolvedinthedegradationofinsulin,renaldysfunctionwillreducetheclearanceofinsulinandprolongitseffect.Thisdecreasedclearanceisseenwithbothendogenousinsulinproduction(eithernormalproductionorthatstimulatedbyoralagents)andexogenousinsulinadministration.Renalfunctiongenerallyneedstobegreatlydiminishedbeforethisbecomesclinicallysignificant .

[28] [29] [30] [31]

[32]

[33] [34] [35]

[36]

[37]

[38]

[

39]

[40]



Pharmacodynamics

Theonset,peak,anddurationofeffectarethemostclinicallysignificantdifferencesamongtheinsulins.Insulinpharmacodynamicsreferstothemetaboliceffectofinsulin.Commerciallyavailableinsulinscanbecategorizedasrapidacting,shortacting,intermediateacting,andlongacting.ThecurrentinsulinsavailableintheUnitedStatesarelistedinTable2.Insulinpharmacodynamics(i.e.,onset,peakandduration)ofthevariousinsulins)areshowninTable3.Itisimportanttonotethatrangesarelistedfortheonset,peakandduration,accountingforintra/interpatientvariability.Eachpatientwillhaveanindividualpatternofresponse.Byhavingthepatientselfmonitortheirbloodglucosefrequently,thepatientspecifictimeactionprofileofthespecificinsulincanbebetterappreciated.Figures4a4c

graphicallyshowthetimeactivityprofilesforthevariousinsulins.

Table2I nsulinsCommerciallyAvailableintheUS

Category/NameofInsulin

Source BrandName(manufacturer) Preparation(s)

RapidActingInsulinLisproInsulinAspartInsulinGlulisine

RecombinantDNARecombinantDNARecombinantDNA

Humalog(Lilly)Novolog(NovoNordisk)Apidra(sanofiaventis)

vial,cartridge,disposablepenvial,cartridge,disposablepenvial,disposablepen

ShortActingRegularHuman

RecombinantDNA HumulinR(Lilly)NovolinR(NovoNordisk)

vialvial

IntermediateActingNPHHuman

RecombinantDNA HumulinN(Lilly)NovolinN(NovoNordisk)

vial,disposablepenvial

LongActingInsulinDetemirInsulinGlargine

RecombinantDNARecombinantDNA

Levemir(NovoNordisk)Lantus(sanofiaventis)

vial,disposablepenvial,cartridge,disposablepen

InsulinMixturesNPH/Regular(70%/30%)HumanLisproProtamine/Lispro(50%/50%)LisproProtamine/Lispro(75%/25%)AspartProtamine/Aspart(70%/30%)

RecombinantDNARecombinantDNARecombinantDNARecombinantDNA

Humulin70/30(Lilly)Novolin70/30(NovoNordisk)HumalogMix50/50(Lilly)HumalogMix75/25(Lilly)NovologMix70/30(NovoNordisk

vial,disposablepenvialvial,disposablepenvial,disposablepenvial,disposablepen

Note:Allinsulinanalogsareavailablebyprescriptiononly.OnAugust17,2009,NovoNordiskannouncedtheNovolinInnoletR,N,and70/30devicesandtheNovolinR,Nand70/30PenFillcartridgeswouldnolongerbeavailableafterDecember31,2009.

Table3I nsulinPharmacodynamics( )

[41] [

42] [43] [44]

[45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57]



Insulin Onset(hr) Peak(hr) Duration(hr) Appearance

InsulinLispro within15min 1 35 Clear

InsulinAspart within15min 13 35 Clear

InsulinGlulisine .25.5 .51 4 Clear

Regular 1 24 58 Clear

NPH 12 410 14+ Cloudy

InsulinDetemir 34 68(thoughrelativelyflat) upto2024 Clear

InsulinGlargine 1.5 flat 24 Clear

LisproMix50/50 .25.5 .53 1424 Cloudy

LisproMix75/25 .255 .52.5 1424 Cloudy

AspartMix70/30 .1.2 14 1824 Cloudy

Note:Patientspecificonset,peak,durationmayvaryfromtimeslistedintable,

Peakanddurationareoftenverydosedependentwithshorterdurationofactionswith

smallerdosesandviceversa.

Figure4a PharmacodynamicProfilesofaRapidInsulinAnalog(insulinlispro)andRegularInsulin.



Figure4b PharmacodynamicProfilesofLongActingandIntermediateActing

BasalInsulins.



Figure4c PharmacodynamicProfile:LisproNPLinComparisonwithNPH

DoseDependentEffect

ThepharmacodynamicsofregularandNPHareparticularlyaffectedbythesizeofthedose .Largerdosescancauseadelayinthepeakandincreasethedurationofaction.Forexample,injecting4unitsofNPHwillhaveasignificantlydifferenttimeactionprofilecomparedto30unitsofNPH.

RapidActingInsulins

InsulinLispro(Humalog)

Insulinlispro[Lys(B28),Pro(B29)]isaninsulinanalogthatwasapprovedin1996(Humalog).TheB28(proline),B29(lysine)aminoacidsequenceoftheinsulinmoleculeisreversedtobelysineprolineresultinginarapidabsorption,within15minutes.Becauseitisabsorbedmorerapidly,itsonsetandpeakaresooner(anddurationshorter)comparedtoregularinsulin.Insulinlisproisalsoapprovedforinjectionimmediatelyafterameal.Becauseinsulinlisprocanbeinjectedjustbefore(orafter)themealversuswaiting30minuteswithregularinsulin,patientsmayfinditprovidesthemwithmoreflexibilityandconveniencefortheirmealtimeinsulininjection.Insulinlisprocanbemoreeffectiveinloweringpostprandialbloodglucoselevelsandhasareducedriskofhypoglycemiacomparedtoregularinsulin

.Thereasoninsulinlisproisassociatedwithlesshypoglycemiaisduetobettermatchingofinsulineffectandfoodabsorption .Insulinlisprohasbeenstudiedforuseininsulinpumpsand,FDAapprovedforthisindicationin2004. .Intherarecaseofseverehumaninsulinallergy,insulinlisprohasbeenshowntobelessimmunogenic .

InsulinAspart(Novolog)

[58]

[59] [

60] [61]

[62]

[63] [64] [65]

[66]



InsulinaspartisahumaninsulinanalogapprovedJune7,2000(Novolog).TheB28aminoacidprolineissubstitutedwithasparticacidresultinginarapidonsetofactivity.Insulinaspartshouldbeinjected510minutesbeforethemeal.Advantageslistedaboveforinsulinlisproarethesameforinsulinaspart .TheinsulinaspartisFDAapprovedforuseininsulinpumps .

Whileonamolarbasisinsulinaspartandlisprohaveidenticalinvivopotencycomparedtoregularhumaninsulin,higherpeakconcentrationsareachievedwiththerapidactinginsulins .Thus,whilea1:1conversionisoftenusedfortheinitialswitchfromregularinsulintoinsulinaspart,glulisineorlispro,overtime,apatientsrapidactinginsulindosemayneedtobeadjusted,oftenreduced.Thisdosingchangeisalsoduetothebettermatchingofthepeakoftheinsulinwiththemeal,thusachievingbetterpostprandialcontrol.

InsulinGlulisine(Apidra)

InsulinglulisineisarapidactinginsulinanaloguethatdiffersfromhumaninsulininthattheaminoacidasparagineatpositionB3isreplacedbylysineandthelysineinpositionB29isreplacedbyglutamicacid.Chemically,itis3Blysine29Bglutamicacidhumaninsulin.Wheninjectedsubcutaneously,itsonsetofactionismorerapidandachieveshigherconcentrationscomparedtohumaninsulinonaunitperunitbasis.Whenusedasamealtimeinsulin,thedoseshouldbegivenwithin15minutesbeforeamealorwithin20minutesafterstartingameal.Insulinglulisinealsoisbeingusedininsulinpumps .InsulinglulisinehasbeenavailableinUSAsince2007andFDAapprovedin2004.

ShortActingInsulin(Regular)

Regularinsulinhasanonsetofactionof3060minutes.Itshouldbeinjectedapproximately30minutesbeforethemeal.Adherencetothisschedulecanbeinconvenientanddifficultforsomepatients.

IntermediateActingInsulins(NPH)

NPH,whichstandsforNeutralProtamineHagedorn,wascreatedin1936byHansChristianHagedornandB.NormanJensen.Thesescientistsdiscoveredthattheeffectsofsubcutaneouslyinjectedinsulincouldbeprolongedbytheadditionofprotamine,aproteinthattheyobtainedfromthe"milt"orsemenofrivertrout.NPHinsuliniscategorizedasanintermediateactinginsulin,whoseonsetofactionisapproximately2hours,peakeffectat614hours,anddurationofactionupto24hours(dependingonthesizeofthedose).Intermediateactinginsulinscanserveabasalinsulinand/orprandialinsulindependingontimeofadministration.NPHinsulinisavailableinvariouscombinationswitheitherregularinsulinorshortactinginsulins(Table2).

LongActingInsulins

Longactinginsulinsservetoprovideabasal(orbaseline)levelofinsulin.

InsulinGlargine(Lantus)

Insulinglargine(21AGly30BaLArg30BbLArghumaninsulin)isaninsulinanalogapprovedApril20,2000(Lantus).Itconsistsoftwomodificationstohumaninsulin.TwoargininesareaddedtotheCterminusoftheBchainshiftingtheisoelectricpointoftheinsulinfromapHor5.4to6.7 .ThischangemakestheinsulinmoresolubleatanacidicpHandinsulinglargineisformulatedatapHof4.0 .ThesecondmodificationisattheA21position,whereasparagineisreplacedbyglycine.Thissubstitutionpreventsdeamidationanddimerisationthatwouldoccurwithacidsensitiveasparagine.Wheninsulinglargineisinjectedintosubcutaneoustissue,whichisatphysiologicpH,theacidicsolutionisneutralized.Microprecipitatesofinsulinglargineareformed,fromwhichsmallamountsofinsulinarereleasedthroughouta24hourperiod,resultinginalowlevelofinsulinthroughouttheday .Thebiologicalactivityofinsulinglargineisduetoitsabsorptionkineticsandnotadifferentpharmacodynamicactivity(e.g.,stimulationofperipheralglucoseuptake) .

Itiscriticalthatinsulinglarginenotbemixedinthesamesyringewithanyanotherinsulinorsolutionbecausethiswill

[67]

[68] [69]

[70]

[71]

[72]

[73]

[74]

[75]



alteritspHandthusaffectitsabsorptionprofile.Lantusmaybegivenatanytimeofday.InsulinglarginehasbeenshowntohavelessnocturnalhypoglycemiawhenusedatbedtimecomparedwithNPHinsulin .

InsulinDetemir(Levemir)

InsulindetemirisalongactinghumaninsulinanalogformaintainingthebasallevelofinsulinitstradenameisLevemir.ItisaninsulinanaloginwhichtheB30aminoacidisomittedandaC14fattyacidchain(myristicacid)isboundtotheB29lysineaminoacid.InsulindetemirisslowlyabsorbedduetoitsstrongassociationwithalbumininthesubQtissueandwhenitreachesthebloodstreamitagainbindstoalbumindelayingitsdistributiontotheperipheraltissues.

Storage

Allinsulinshaveanexpirationdatewhichislabeledondirectlyontheproduct(vials,cartridges,disposablepensandotherdeliverydevices)applieswhentheyareunopenedandrefrigerated.Unopened(i.e.,insulinnotcurrentlyinuse)insulinshouldbestoredintherefrigeratorat36F46F(2C8C).Insulinshouldneverbefrozenorstoredinanambienttemperaturegreaterthan86F(30C).Aninsulinvialinusemaybekeptatroomtemperature,below86F,or30C(insulinglulisineandNovoNordiskhumaninsulins,N,Rand70/30,shouldbestoredupto77Fonly),for28days,orabout1month(exceptforinsulindetemirandNovoNordiskhumaninsulins,whichcanbekeptforupto42days).Insulincartridges,disposablepensandotherdeliverydevicescanhavedifferentstoragerecommendationsforroomtemperature.Onceopened,insulincartridgesandpensshouldnotberefrigerated.

AdverseEffects

Themostsignificantadverseeffectofinsulinishypoglycemia.IntheDCCT(DiabetesControlandComplicationsTrial),intensiveinsulintherapywasassociatedwitha23foldincreaseinseverehypoglycemia(i.e.,apersonrequiringassistance) .Likewise,intheUKPDS(UnitedKingdomProspectiveDiabetesStudy),insulintherapyintheintensivelytreatedgroupresultedin1.8%rateofmajorhypoglycemicepisodescomparedto0.7%intheconventionalgroup .Allpatientsreceivinginsulinshouldbeawareofthesymptomsofhypoglycemiaandhowtotreatit.

Weightgainisanothersignificantsideeffectofinsulintherapy.Inpart,theweightgaincanbearesultoffrequenthypoglycemicepisodesinwhichpatientsoftenovertreat/overeatinresponsetohunger.Insulin,beingananabolichormone,alsopromotestheuptakeoffattyacidsintoadiposetissue.TheamountofweightgainintheDCCTandUKPDSassociatedwithinsulintherapywas4.6kgand4.0kgrespectively .However,lessweightgainisencounteredwithlongactinginsulinanalogs .

Trueallergicreactionsandcutaneousreactionsarerare(seeImmunogenicity).Toavoidlipohypertrophy,patientsshouldbeinstructedtorotatetheirinsulininjectionsites,preferablyrotatingwithinonearea(e.g.,abdomenavoid2inchradiusaroundnavel)andnotreusingforoneweek .

InJune2009,4retrospective,epidemiologicstudiesassessingtheriskofcancerfrominsulinuse,glargineinparticular,werepublishedonlineattheEuropeanAssociationfortheStudyofDiabetes'journalwebsite3oftheseEuropeanstudiesreportedanincreasedriskofcancerwithinsulinglargine.IntheGermanystudy,acorrelationbetweeninsulindoseandcancerriskwasfoundforallinsulintypes(humaninsulin,aspart,lisproorglargine)howeverafteradjustingfordose,insulinglarginewasfoundtohaveadosedependentincreasedriskofcancercomparedtohumaninsulin(e.g.,HR1.09,1.19and1.31foratotaldailydosesof10units,30unitsand50unitsrespectively). Themedianfollowuptimewasonly1.63years(1.31yearsforinsulinglargine)andbodymassindexwasnotaccountedfor.TheSwedishstudyfoundastatisticallysignificantincreasedriskofbreastcanceronlyinwomenwhousedinsulinglarginealone(RR1.99),butnotinthoseoninsulinglargineplusotherinsulins. TheScotlandstudydemonstratedaincreasedriskofcancer(HR1.55)forpatientsoninsulinglarginealone,whilethoseoninsulinglargineplusotherinsulinshadaslightlylowerincidenceofcancer(HR0.81)comparedtohumaninsulinonlyuserswhichwasnotstatisticallysignificant.

[76] [77]

[78]

[79]

[80] [81]

[82] [83]

[84]

[85]

[86]

[87]

[88]



Finally,intheUKstudy,nolinkbetweeninsulinglargineandcancerwasfound. Theseobservationalstudiesassessedlargepatientdatabasesandhavesignificant,inherentlimitationstogeneralizetheirconclusions,suchasthepotentialfordifferentpretreatmentcharacteristicsofthegroups,selectionbias,thesmallnumbersofcancercasesfound,andshortdurationoffollowup.Also,type2diabetesitselfisassociatedwithanincreasedriskofcolon,pancreasandbreastcancer.Furthermore,inarandomised,5year,openlabeltrialcomparingtheprogressionofretinopathyofNPHandinsulinglargineusers,noincreasedriskofcancerwasfoundinthe1017patientsample. Lastly,inananalysisof31randomizedcontrolledtrialsfromthesanofiaventissafetydatabase(phase2,3,and4studies),insulinglarginewasnotassociatedwithanincreasedriskofcancer,includingbreastcancer. Ofnote,themainstudyaffectingthesefindingsistheRosenstocketalstudycomparingglarginetoNPHthathadanapproximate5yearduration,whereas19ofthestudiesincludedhadveryshortdurations(approximately6months).OnJuly1,2009,theFDAissuedanearlycommunicationaboutthesafetyofLantusandisworkingwiththemanufacturertoreviewthecollectivedataanddeterminewhetheradditionalstudiesneedtobeperformed.Atthistime,thesedatadonotprovideconclusiveevidenceofanincreasedriskofcancerassociatedwithinsulinglargine.

TYPESOFREGIMENS

GeneralPrinciples

Type1Diabetes

Withdecreasingbetacellfunctionresultingindecreasedinsulinproduction,peoplewithtype1diabetesmayrequireinsulinforsurvival.Ingeneral,insulinopenictype1diabeticsgenerallyrequire0.51.0unitsperkgofbodyweightperdayofinsulin .Insulintherapyisofteninitiatedat0.50.75units/kg/day .Duringtheearlystagesoftype1diabetes,patientswillrequirelessinsulinbecausethebetacellsarestillproducingsomeinsulininsulinrequirementscanbeintherangeof0.10.6unitsperkgperday .Intensiveinsulintherapy(definedas3insulininjectionsdaily)isindicatedforpeoplewithtype1diabetesasthishasbeenshowntoprovidebetterglycemiccontrolthan1or2dailyinjectionsandreducethedevelopmentandprogressionofmicrovascularcomplications .

Type2Diabetes

Manypatientswithtype2diabeteswilleventuallyrequireinsulintherapy.Sincetype2diabetesisassociatedwithinsulinresistance,insulinrequirementscanexceed1unit/kg/day.IntheUKPDS,by9yearslessthan25%ofpatientstreatedwithasulfonylureaasmonotherapywereabletomaintainA1Clevels



Preprandialplasmaglucose70130mg/dl

Postprandialplasmaglucose



Figure5a.

Figure5b.

Figure5c.

TwicedailyInsulinRegimen(SplitMixedandPreMixedRegimens)

Twothirdsoftheinsulindoseisgiveninthemorningbeforebreakfastandonethirdisgivenbeforedinner.Premixedinsulinscanbeusedoramixtureofashortactinginsulin(e.g.,regular,insulinaspart/glulisine/lispro)andanintermediateactinginsulin(e.g.,NPH)(Figure6a) .[106]



Figure6a.

2/3totaldailydoseatbreakfast:givenas2/3NPHand1/3Regular(orinsulinaspart/glulisine/lispro)

1/3totaldailydoseatdinner:dividedinequalamountsofNPHandRegular(orinsulinaspart/glulisine/lispro)

ForpatientswhoexperiencenocturnalhypoglycemiawhenNPHisadministeredatdinnerwithashortactinginsulin,movingtheNPHdosetobedtimehelpsreducetheriskfornocturnalhypoglycemia .Conversely,NPHatdinnercanresultinfastinghyperglycemiaduetodissipationofinsulinactivityandthedawnphenomenon.MovingtheNPHdosetobedtimecanhelpresolvethisproblem (Figure6b).Anobviouslimitationtousingpremixedinsulinisreducedflexibilityindosingifthedoseisadjusted,bothtypesofinsulininthemixtureareadjusted.

Figure6b.

MultipleDailyInsulinInjectionRegimen:BasalplusPrandialInsulin

Manydifferenttypesofregimensarepossiblewithmultipledailyinjections.Regular,insulinaspart,glulisineandlisproareusedtoprovideprandialinsulin.NPH,insulinglargine,andinsulindetemirareusedtoprovidebasalinsulin.

Regular,insulinaspart/glulisine/lisprobeforemealsandNPH,insulinglargineorinsulindetemiratbedtime(Figure7a,7b).

Insulinaspart/glulisine/lisprobeforemealsandNPHtwicedaily(breakfastandbedtime)(Figure8).

[107]

[108]



Figure7a.

Figure7b.

Figure8.

InsulinPumps

Insulinpumporcontinuoussubcutaneousinsulininfusion(CSII)therapyisanotheroptionforintensiveinsulintherapy.Whilepumptherapyusedtobereservedforprimarilytype1diabetes,patientswithtype2diabetesarenowusinginsulinpumps .Patientsinitiatedoninsulinpumptherapyneedtobeveryknowledgeableaboutdiabetesmanagementandbepracticingselfmanagement.Patientsalreadyknowhowtocountcarbohydratesandadjusttheir

[109]



insulindoses.Potentialadvantagesofinsulinpumpsincludelessweightgain,lesshypoglycemia,andbettercontroloffastinghyperglycemiaduetothedawnphenomenoncomparedtomultipledailyinjections .

TimingofPrandialInsulinInjection

Thelagtimefrominjectingregularinsulinandeatingisapproximately30minuteswhileinsulinaspart/glulisine/lisprocanbeinjectedwithin15minutesofeating.Dependingonthelevelofhyperglycemiabeforemeals,thelagtimecanbeincreased.Rapidactinginsulinsallowpatientstoadjustinsulintomatchtheirlifestyleratherthanhavingtoadaptthetimingofmealstoamorefixedinsulinregimen .

Adjustments

Insulindosesshouldbeadjustedtoachieveglycemictargets.Itisalwaysbesttoerrontheconservativesidewhendosinginsulinatinitiationorwhenadjustingcurrentinsulintherapy.Typicallya1020%increaseordecreaseinaninsulindoseisappropriate.Ifapatientisexperiencinghypoglycemia,adjustmentoftheinsulindosecausingthehypoglycemiashouldbeaddressedpreferentiallyoverotherinsulindoseadjustments.Hyperglycemiaisadominoeffect:ifapatientishyperglycemicinthemorning,chancesaretheyremainhyperglycemicthroughouttheday.Therefore,adjusttheearliesttimeofhyperglycemiafirst .

AdjustmentofIntermediatetoLongActingInsulin

Whenadoseofintermediateorlongactinginsulinisadjusted,itisrecommendedtowaitatleast25daysbeforefurtherchangesinthedosetoassesstheresponse .

AdjustmentofOnceDailyEveningInsulin

TheFPGisusedtoadjusttheintermediatetolongactinginsulingivenintheevening.Acommonweeklytitrationscheduleusedis :

IftheFPGis>140mg/dl:Increaseby4units

IftheFPGis120140mg/dl:Increaseby2units

Forinsulinglargine,thefollowingtitrationschedulehasbeenstudiedandshowntocauselessnocturnalhypoglycemiacomparedtobedtimeNPHinsulin.Inthisstudy,insulinwastitrated,usingaforcedtitrationschedule,totargetaFPGof100mg/dl .

ForcedTitrationScheduleStartwith10unitsbedtimebasalinsulindoseadjustweekly

FPG(mg/dL) Increaseinsulindose

100120 2

120140 4

140180 6

180 8

Decreaseinsulindose(e.g.,24units/day)ifhypoglycemiaoccurs.(modifiedrecommendationfromreference112)

SupplementalInsulinforCorrectionofHyperglycemia

Regularinsulin,insulinaspart/glulisine/lisprocanbeusedtocorrectforhyperglycemia .Ingeneral,12unitsofinsulinwilllowerthebloodglucoseby3050mg/dl.Often1unitforevery50mg/dlabovetheglucosetargetisastartingsupplementaldose,adjustingforinsulinsensitivity .Anexampleofasupplementalinsulinregimenisasfollows:Forevery50mg/dlabovethepremealglucosetarget(e.g.,150mg/dl),add1unitofinsulin .So,ifa

[110] [111] [112] [113]

[114]

[115]

[116]

[117]

[118]

[119]

[120]

[121]



1.

2.

3.

4.

personspremealglucosewas250mg/dl,2unitsofinsulinwouldbeaddedtotheusualdoseofpremealinsulin.Supplementalinsulincanalsobeusedforsnacks .

CarbohydrateCounting

Amoresophisticatedtypeofinsulinregimenisoneinwhichapatientdosestheirprandialinsulinbasedonthenumberofcarbohydrateseatenatthemeal.Bylearninghowtocounttheircarbohydrates,anddosingtheirinsulinaccordingly,patientsareaffordedflexibilityintheirmeals.Astartinginsulintocarbohydraterationoftenusedis1unitofinsulinforevery15gramsofcarbohydrate .Thisratioisadjustedbasedoninsulinsensitivityandmaybedifferentforeachmeal.Carbohydratecountingistoodifficultforsomepatients.Inthesepatients,mealportionsizesandestimatesofcarbohydrateservings(15grams)areconceptsthatcanbelearned.Medicalnutritiontherapyisacriticalcomponentoftherapyforpatientsoninsulin.

Acomprehensivediabeteseducationclass,thatteachesselfmanagementskills,suchashowtodoseprandialinsulinbymatchingittotheamountofcarbohydrateintakeareanexcellentresourcetofacilitatepatientsinadoptinganintensiveinsulintherapyregimen .

AdjustmentsforExercise

Exerciseimprovesinsulinsensitivity.Thus,whenapatientexercises,itisoftennecessarytodecreasetheinsulindose(andincreasecaloricintake).Formorningexercise,theprebreakfastinsulindoseshouldbereduced(~25%dependingonthedurationandintensityoftheexercise).Forlatemorning/earlyafternoonandeveningexercise,theprelunchandpredinnerinsulindoseshouldbereducedrespectively .Theeffectofexerciseoninsulinsensitivitycanlastformanyhourssoseveralinsulindosesmayneedtobeadjusted.

SelfMonitoringofBloodGlucose

Patientswhowerenotselfmonitoringtheirbloodglucose(SMBG)levelspriortoinsulinneedtobeeducatedhowtodothis,howtointerprettheirglucosereadings,andhowtotreathypoglycemiaifitoccurs.Involvementofdiabeteseducatorisextremelyusefulwheninitiatingpatientsoninsulintoprovidecomprehensiveselfmanagementtraining.TheADAcurrentlyrecommendthatpeoplewithtype1diabetesSMBGatleast3timesdailyandthosewithtype2diabetesatleastdaily .Mostglucosemetersarenowplasmareferenced,correlatingbettertotheADAsglycemicgoals.Plasmaglucoseconcentrationsareapproximately1015%higherthanwholebloodglucoseconcentrations .

SICKDAYGUIDELINES

Acommonmisconceptionamongpatientsisthatiftheyaresickenoughthattheydonteatorevenvomit,theyshouldnottaketheirdiabetesmedications,insulinincluded.Patientsshouldbeinstructedtocontinuetheirinsulintherapy,maintainfluidintake,eatsmallermealsastolerated,andtesttheirglucoselevelsevery14hours(ketonesaswellforpeoplewithtype1diabetes).Insulintherapyshouldbeadjustedbasedontheglucoselevels.Iftheglucoseis>240mg/dlwithmoderatetolargeketonuria,patientsshouldcontacttheirproviderimmediately .

References

BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.FDA/CDERresourcespage.Frequentlyaskedquestionsaboutimportingbeeforporkinsulinforpersonaluse.FoodandDrugAdministrationwebsite.Availableat:http://www.fda.gov/cder/drug/beefandporkinsulin/default.htm.AccessedSeptember16,2006.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.May2004EliLillyandCompany.HumalogPackageInsert.

[122]

[123]

[124]

[125]

[126]

[127]

[128]



5.6.7.8.9.10.11.12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.23.

24.

25.

26.

27.

28.29.30.31.

32.33.

34.

March2005EliLillyandCompany.HumalogMix75/25PackageInsert.February2006SanofiAventisU.S.LantusPackageInsert.October2005NovoNordisk,Inc.NovologPackageInsert.November2005NovoNordiskInc.NovologMix70/30PackageInsert.January2006EliLillyandCompany.HumalogMix50/50PackageInsert.October2005NovoNordiskInc.LevemirPackageInsert.November2005AventisPharmaceuticalsInc.ApidraPackageInsert.KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenicpotenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenicpotenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.[PubMed:12324987]SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]SchernthanerG1993Immunogenicityandallergenicpotentialofanimalandhumaninsulins.DiabetesCare16Suppl3:15565.[PubMed:8299472]March2007sanofiaventisU.S.LCC.LantusPackageInsert.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.KroonLA,AssemiM,CarlisleBA.2009DiabetesMellitus.In:AppliedTherapeutics:TheClinicalUseofDrugs,9thedition.KodaKimbleMA,YoungLY,AlldredgeBA,CorelliRL,GuglielmoBJ,KradjanWA,WilliamsBR,eds.Lippincott,Williams&Wilkins:Baltimore,MD.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.March2009EliLillyandCompany.HumalogPackageInsert.March2008NovoNordisk,Inc.NovologPackageInsert.February2009sanofiaventisU.S.LCC.ApidraPackageInsert.terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsandglucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]March2007sanofiaventisU.S.LCC.LantusPackageInsert.BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenic



35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.46.47.48.49.50.51.

52.

53.

54.

55.

56.

57.

58.

59.

potenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.[PubMed:12324987]BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.FrancisAJ,HanningI,AlbertiKG1985Theinfluenceofinsulinantibodylevelsontheplasmaprofilesandactionofsubcutaneouslyinjectedhumanandbovineshortactinginsulins.Diabetologia28:3304.[PubMed:3899818]terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsandglucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]NolteMS,Karam,J.H.2001PancreaticHormones&AntidiabeticDrugs.In:KatzungB(ed)BasicandClinicalPharmacology,8thed.LangeMedicalBooks/McGrawHill,NewYork,pp711734.RabkinR,RyanMP,DuckworthWC1984Therenalmetabolismofinsulin.Diabetologia27:3517.[PubMed:6389240]RoachP,WoodworthJR2002Clinicalpharmacokineticsandpharmacodynamicsofinsulinlispromixtures.ClinPharmacokinet41:104357.[PubMed:12403642]RaveK,etal.2005Timeactionprofileofinhaledinsulinincomparisonwithsubcutaneouslyinjectedinsulinlisproandregularhumaninsulin.DiabetesCare2810771082.[PubMed:15855570]PlankJ,etal.2005.Adoubleblind,randomized,doseresponsestudyinvestigatingthepharmacodynamicandpharmacokineticpropertiesofthelongactinginsulinanalogdetemir.DiabetesCare2811071112.[PubMed:15855574]LeporeM,etal.2000.Pharmacokineticsandpharmacodynamicsofsubcutaneousinjectionoflongactinghumaninsulinanalogglargine,NPHinsulin,andultralentehumaninsulinandcontinuoussubcutaneousinfusionofinsulinlispro.Diabetes4921422148.[PubMed:11118018]March2009EliLillyandCompany.HumalogPackageInsert.March2009EliLillyandCompany.HumalogMix75/25PackageInsert.March2007sanofiaventisU.S.LCC.LantusPackageInsert.March2008NovoNordisk,Inc.NovologPackageInsert.October2007NovoNordiskInc.NovologMix70/30PackageInsert.May2007NovoNordiskInc.LevemirPackageInsert.KurtzhalsP,SchafferL,SorensenA,etal.2000Correlationsofreceptorbindingandmetabolicandmitogenicpotenciesofinsulinanalogsdesignedforclinicaluse.Diabetes49:9991005.[PubMed:10866053]HomePD,AshwellSG2002Anoverviewofinsulinglargine.DiabetesMetabResRev18Suppl3:S5763.[PubMed:12324987]KroonLA,AssemiM,CarlisleBA.2009DiabetesMellitus.In:AppliedTherapeutics:TheClinicalUseofDrugs,9thedition.KodaKimbleMA,YoungLY,AlldredgeBA,CorelliRL,GuglielmoBJ,KradjanWA,WilliamsBR,eds.Lippincott,Williams&Wilkins:Baltimore,MD,pp5017.terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsandglucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]FrancisAJ,HanningI,AlbertiKG1985Theinfluenceofinsulinantibodylevelsontheplasmaprofilesandactionofsubcutaneouslyinjectedhumanandbovineshortactinginsulins.Diabetologia28:3304.[PubMed:3899818]NolteMS,Karam,J.H.2001PancreaticHormones&AntidiabeticDrugs.In:KatzungB(ed)BasicandClinicalPharmacology,8thed.LangeMedicalBooks/McGrawHill,NewYork,pp711734.RabkinR,RyanMP,DuckworthWC1984Therenalmetabolismofinsulin.Diabetologia27:3517.[PubMed:6389240]BinderC,BrangeJ1997Insulinchemistryandpharmacokinetics.In:PorteD,Jr.,SherwinR(eds)Ellenberg'sandRifkin'sDiabetesMellitus,5theditioned.AppletonandLange,Stamford,CT,p689.PampanelliS,TorloneE,IalliC,etal.1995ImprovedpostprandialmetaboliccontrolaftersubcutaneousinjectionofashortactinginsulinanaloginIDDMofshortdurationwithresidualpancreaticbetacellfunction.Diabetes



60.

61.

62.

63.

64.

65.

66.

67.

68.69.

70.

71.72.73.74.

75.

76.

77.

78.

79.

Care18:14529.[PubMed:8722069]BrunelleBL,LlewelynJ,AndersonJH,Jr.,GaleEA,KoivistoVA1998Metaanalysisoftheeffectofinsulinlisproonseverehypoglycemiainpatientswithtype1diabetes.DiabetesCare21:172631.[PubMed:9773738]LalliC,CiofettaM,DelSindacoP,etal.1999Longtermintensivetreatmentoftype1diabeteswiththeshortactinginsulinanaloglisproinvariablecombinationwithNPHinsulinatmealtime.DiabetesCare22:46877.[PubMed:10097931]LalliC,CiofettaM,DelSindacoP,etal.1999Longtermintensivetreatmentoftype1diabeteswiththeshortactinginsulinanaloglisproinvariablecombinationwithNPHinsulinatmealtime.DiabetesCare22:46877.[PubMed:10097931]ZinmanB,TildesleyH,ChiassonJL,TsuiE,StrackT1997InsulinlisproinCSII:resultsofadoubleblindcrossoverstudy.Diabetes46:4403.[PubMed:9032100]KaufmanFR,HalvorsonM,KimC,PitukcheewanontP2000Useofinsulinpumptherapyatnighttimeonlyforchildren710yearsofagewithtype1diabetes.DiabetesCare23:57982.[PubMed:10834412]RennerR,PfutznerA,TrautmannM,HarzerO,SauterK,LandgrafR1999Useofinsulinlisproincontinuoussubcutaneousinsulininfusiontreatment.Resultsofamulticentertrial.GermanHumalogCSIIStudyGroup.DiabetesCare22:7848.[PubMed:10332682]KumarD1997Lisproanalogfortreatmentofgeneralizedallergytohumaninsulin.DiabetesCare20:13579.[PubMed:9283778]RaskinP,GuthrieRA,LeiterL,RiisA,JovanovicL2000Useofinsulinaspart,afastactinginsulinanalog,asthemealtimeinsulininthemanagementofpatientswithtype1diabetes.DiabetesCare23:5838.[PubMed:10834413]March2008NovoNordisk,Inc.NovologPackageInsert.BodeBW,StrangeP2001Efficacy,safety,andpumpcompatibilityofinsulinaspartusedincontinuoussubcutaneousinsulininfusiontherapyinpatientswithtype1diabetes.DiabetesCare24:6972.[PubMed:11194244]terBraakEW,WoodworthJR,BianchiR,etal.1996Injectionsiteeffectsonthepharmacokineticsandglucodynamicsofinsulinlisproandregularinsulin.DiabetesCare19:143740.[PubMed:8941480]February2009sanofiaventisU.S.LCC.ApidraPackageInsert.BolliGB,OwensDR2000Insulinglargine.Lancet356:4435.[PubMed:10981882]BolliGB,OwensDR2000Insulinglargine.Lancet356:4435.[PubMed:10981882]HeinemannL,LinkeschovaR,RaveK,HompeschB,SedlakM,HeiseT2000Timeactionprofileofthelongactinginsulinanaloginsulinglargine(HOE901)incomparisonwiththoseofNPHinsulinandplacebo.DiabetesCare23:6449.[PubMed:10834424]MudaliarS,MohideenP,DeutschR,etal.2002.Intravenousglargineandregularinsulinhavesimilareffectsonendogenousglucoseoutputandperipheralactivation/deactivationkineticprofiles.DiabetesCare25:1597602.[PubMed:12196433]YkiJarvinenH,DresslerA,ZiemenM.2000.LessnocturnalhypoglycemiaandbetterpostdinnerglucosecontrolwithbedtimeinsulinglarginecomparedwithbedtimeNPHinsulinduringinsulincombinationtherapyintype2diabetes.HOE901/3002StudyGroup.DiabetesCare23:11306.[PubMed:10937510]RatnerRE,HirschIB,NeifingJL,GargSK,MeccaTE,WilsonCA2000Lesshypoglycemiawithinsulinglargineinintensiveinsulintherapyfortype1diabetes.U.S.StudyGroupofInsulinGlargineinType1Diabetes.DiabetesCare23:63943.[PubMed:10834423]TheDiabetesControlandComplicationsTrialResearchGroup.1993.Theeffectofintensivetreatmentofdiabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed329:97786.[PubMed:8366922]UKProspectiveDiabetesStudy(UKPDS)Group.1998.Intensivebloodglucosecontrolwithsulphonylureasorinsulincomparedwithconventionaltreatmentandriskofcomplicationsinpatientswithtype2diabetes(UKPDS33).Lancet352:83753.[PubMed:9742976]



80.

81.

82.

83.

84.

85.

86.

87.

88.

89.

90.

91.

92.

93.

94.95.

96.

97.

TheDiabetesControlandComplicationsTrialResearchGroup.1993.Theeffectofintensivetreatmentofdiabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed329:97786.[PubMed:8366922]

UKProspectiveDiabetesStudy(UKPDS)Group.1998.Intensivebloodglucosecontrolwithsulphonylureasorinsulincomparedwithconventionaltreatmentandriskofcomplicationsinpatientswithtype2diabetes(UKPDS33).Lancet352:83753.[PubMed:9742976]MeneghiniLF,RosenbergKH,KoenenC,MerilainenMJ,LddekeHJ.2007.Insulindetemirimprovesglycaemiccontrolwithlesshypoglycaemiaandnoweightgaininpatientswithtype2diabeteswhowereinsulinnaiveortreatedwithNPHorinsulinglargine:clinicalpracticeexperiencefromaGermansubgroupofthePREDICTIVEstudy*Diabetes,ObesityandMetabolism9(3)418427.[PubMed:17391170]RosenstockJ,DaviesM,HomePD,LarsenJ,KoenenC,SchernthanerG.2008.Arandomised,52week,treattotargettrialcomparinginsulindetemirwithinsulinglarginewhenadministeredasaddontoglucoseloweringdrugsininsulinnaivepeoplewithtype2diabetes.Diabetologia51(3):408416.[PMCfreearticle:PMC2235909][PubMed:18204830]ADA.2004.AmericanDiabetesAssociationPositionStatement.Insulinadministration.DiabetesCare27Suppl1:S106109.[PubMed:14693942]HemkinsLG,GrouvenU,BenderRetal.2009.Riskofmalignanciesinpatientswithdiabetestreatedwithhumaninsulinorinsulinsanalogues:acohortstudy.Diabetologia52:17321744.[PMCfreearticle:PMC2723679][PubMed:19565214]JonassonJM,LjungR,TlbackMetal.2009.InsulinglargineuseandshorttermincidenceofmalignanciesapopulationbasedfollowupstudyinSweden.Diabetologia52:17451754.[PubMed:19588120]ColhounHM,onbehalfoftheSDRNEpidemiologyGroup.2009.UseofinsulinglargineandcancerincidenceinScotland:astudyfromtheScottishDiabetesResearchNetworkEpidemiologyGroup.Diabetologia52:17551765.[PMCfreearticle:PMC2723678][PubMed:19603149]CurrieCJ,PooleCD,2009.GaleEAMTheinfluenceofglucoseloweringtherapiesoncancerriskintype2diabetes.Diabetologia52:17661777.[PubMed:19572116]RosenstockJ,FonsecaV,McGillJBetal.2009.SimilarriskofmalignancywithinsulinglargineandneutralprotamineHagedorn(NPH)insulininpatientswithtype2diabetes:findingsfroma5yearrandomized,openlabelstudy.Diabetologia52:17781788.[PMCfreearticle:PMC2723677][PubMed:19609501]HomePD,LagarenneP.2009.Combinedrandomisedcontrolledtiralexperienceofmalignanciesinstudiesusinginsulinglargine.Diabetologiadoi:10.1007/s0012500915305.[PMCfreearticle:PMC2776153][PubMed:19756478]HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,23556.[PubMed:10593324]HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,23556.[PubMed:10593324]ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.2002Practicalinsulin:Ahandbookforprescribingproviders.AmericanDiabetesAssociation,Alexandria,VA.1993TheDiabetesControlandComplicationsTrialResearchGroup.Theeffectofintensivetreatmentofdiabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed329:97786.[PubMed:8366922]TurnerRC,CullCA,FrighiV,HolmanRR1999Glycemiccontrolwithdiet,sulfonylurea,metformin,orinsulininpatientswithtype2diabetesmellitus:progressiverequirementformultipletherapies(UKPDS49).UKProspectiveDiabetesStudy(UKPDS)Group.Jama281:200512.[PubMed:10359389]HermannLS2000Optimisingtherapyforinsulintreatedtype2diabetesmellitus.DrugsAging17:28394.[PubMed:11087006]



98.

99.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.115.

116.

117.

118.

119.

HermannLS2000Optimisingtherapyforinsulintreatedtype2diabetesmellitus.DrugsAging17:28394.[PubMed:11087006]

DeWittDE,DugdaleDC2003Usingnewinsulinstrategiesintheoutpatienttreatmentofdiabetes:clinicalapplications.Jama289:22659.[PubMed:12734138]YkiJarvinenH2001Combinationtherapieswithinsulinintype2diabetes.DiabetesCare24:75867.[PubMed:11315844]ADA2009Standardsofmedicalcareindiabetes2009.DiabetesCare32Suppl1:S1361.[PMCfreearticle:PMC2613589][PubMed:19118286]1993TheDiabetesControlandComplicationsTrialResearchGroup.Theeffectofintensivetreatmentofdiabetesonthedevelopmentandprogressionoflongtermcomplicationsininsulindependentdiabetesmellitus.NEnglJMed329:97786.[PubMed:8366922]RoachP,WoodworthJR2002Clinicalpharmacokineticsandpharmacodynamicsofinsulinlispromixtures.ClinPharmacokinet41:104357.[PubMed:12403642]ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.FanelliCG,PampanelliS,PorcellatiF,RossettiP,BrunettiP,BolliGB2002AdministrationofneutralprotamineHagedorninsulinatbedtimeversuswithdinnerintype1diabetesmellitustoavoidnocturnalhypoglycemiaandimprovecontrol.Arandomized,controlledtrial.AnnInternMed136:50414.[PubMed:11926785]FrancisAJ,HomePD,HanningI,AlbertiKG,TunbridgeWM1983Intermediateactinginsulingivenatbedtime:effectonbloodglucoseconcentrationsbeforeandafterbreakfast.BrMedJ(ClinResEd)286:11736.[PMCfreearticle:PMC1547399][PubMed:6404377]RaskinP,BodeBW,MarksJB,etal.2003Continuoussubcutaneousinsulininfusionandmultipledailyinjectiontherapyareequallyeffectiveintype2diabetes:arandomized,parallelgroup,24weekstudy.DiabetesCare26:2598603.[PubMed:12941725]MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.[PubMed:11727406]BodeBW,SabbahHT,GrossTM,FredricksonLP,DavidsonPC2002Diabetesmanagementinthenewmillenniumusinginsulinpumptherapy.DiabetesMetabResRev18Suppl1:S1420.[PubMed:11921425]BodeBW,TamborlaneWV,DavidsonPC2002Insulinpumptherapyinthe21stcentury.Strategiesforsuccessfuluseinadults,adolescents,andchildrenwithdiabetes.PostgradMed111:6977quiz27.[PubMed:12040864]PickupJ,KeenH2002Continuoussubcutaneousinsulininfusionat25years:evidencebasefortheexpandinguseofinsulinpumptherapyintype1diabetes.DiabetesCare25:5938.[PubMed:11874953]February2009.sanofiaventisU.S.LCC.ApidraPackageInsert.ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.[PubMed:11727406]RiddleMC,RosenstockJ,GerichJ2003Thetreattotargettrial:randomizedadditionofglargineorhumanNPHinsulintooraltherapyoftype2diabeticpatients.DiabetesCare26:30806.[PubMed:14578243]HollemanF,vandenBrandJJ,HovenRA,etal.1996ComparisonofLysB28,ProB29humaninsulinanalog



120.

121.

122.

123.

124.

125.

126.

127.

128.

andregularhumaninsulininthecorrectionofincidentalhyperglycemia.DiabetesCare19:14269.[PubMed:8941477]MudaliarS,EdelmanSV2001Insulintherapyintype2diabetes.EndocrinolMetabClinNorthAm30:93582.[PubMed:11727406]DeWittDE,HirschIB2003Outpatientinsulintherapyintype1andtype2diabetesmellitus:scientificreview.Jama289:225464.[PubMed:12734137]KongN,KitchenMM,RyderRE2000Theuseoflisproforhighsugarcontentsnacksbetweenmealsinintensiveinsulinregimens.DiabetMed17:3312.[PubMed:10821304]HirschIB1999Type1diabetesmellitusandtheuseofflexibleinsulinregimens.AmFamPhysician60:234352,23556.[PubMed:10593324]2002Traininginflexible,intensiveinsulinmanagementtoenabledietaryfreedominpeoplewithtype1diabetes:doseadjustmentfornormaleating(DAFNE)randomisedcontrolledtrial.Bmj325:746.[PMCfreearticle:PMC128375][PubMed:12364302]ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.ADA2009Standardsofmedicalcareindiabetes2009.DiabetesCare32Suppl1:S1361.[PMCfreearticle:PMC2613589][PubMed:19118286]StahlM,BrandslundI,JorgensenLG,HyltoftPetersenP,BorchJohnsenK,deFineOlivariusN2002Cancapillarywholebloodglucoseandvenousplasmaglucosemeasurementsbeusedinterchangeablyindiagnosisofdiabetesmellitus?ScandJClinLabInvest62:15966.[PubMed:12004932]ADA1998MedicalManagementofInsulinDependent(TypeI)DiabetesMellitus,3rdeditioned.AmericanDiabetesAssociation,Alexandria,VA.

Copyright20002015,MDText.com,Inc.

ThiselectronicversionhasbeenmadefreelyavailableunderaCreativeCommons(CCBYNCND)license.Acopyofthelicensecanbeviewedathttp://creativecommons.org/licenses/byncnd/2.0/.

BookshelfID:NBK278938 PMID:25905175

insulin – pharmacology, types of regimens, and adjustments

Documents